Research spanning more than 20 years has led the UPV/EHU's Neurochemistry and Neurodegeneration group under Dr. Rafael Rodríguez-Puertas to discover a promising avenue for the development of new ...

As the year unfolds the biotech industry will look closely at these ten first-in-class drugs on track to reach FDA approval ...

Scientists have come up with a drug that is a potential candidate for tackling memory deficits in the early stages of the disease in rodents. Research shows that the drug activates the cannabinoid ...

A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the initial cognitive damage caused by dementia, and explains how it works ...

Research highlights the therapeutic potential of targeting cannabinoid receptors to counter memory impairment in early ...

A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the ...

Irritable bowel syndrome is the most common cause of chronic diarrhea and lower abdominal discomfort in North America.

SEOUL, Jan. 9 (Korea Bizwire) — Scientists have discovered that the brain region associated with movement disorders like ...

To identify this year’s Drugs to Watch 2025 list, Clarivate drew from expertise from over 160 Clarivate analysts covering ...

Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care LONDON, Jan. 8, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading ...

the approval of COBENFY marks a transformative milestone as the first drug in over 30 years with a novel mechanism of action ...

You might just know someone, close or distant, who has struggled with drug addiction at one point in time. It could be a distant relative or someone you went to school with, but the sheer probability ...